Study of FKC289 for AL amyloidosis that has returned or not responded
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new treatment called FKC289 for people with AL amyloidosis that has come back or hasn't improved with standard treatments. The goal is to see if it is safe and helps patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with AL amyloidosis (a protein buildup disease) and it has returned or didn't respond to previous treatments.
- Your blood test shows a certain level of abnormal light chain proteins (dFLC ≥ 40 mg/L).
- You are able to care for yourself (ECOG score 0-2).
- You have not had a serious infection in the last 2 weeks, and your major organs (like heart, kidneys, liver, lungs) are working well enough.
- You have not had cancer in the last 5 years, except for certain types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called FKC288 for people with AL amyloidosis that hasn't been helped by standard treatments. The goal is to see if it can safely control the disease and improve organ function.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new Primary Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.